A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-701 in Healthy Adult Western and Asian Subjects
Latest Information Update: 11 Dec 2025
At a glance
- Drugs ABBV 701 (Primary) ; ABBV 701 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 28 Nov 2025 Treatment arms are increased from 7 to 12 by the addition of 3 more experimental arms for part 3 and 2 more experimental arms for part 4, comprising ABBV-701 IV infusion.
- 28 Nov 2025 Planned number of patients changed from 58 to 100.
- 04 Apr 2025 New trial record